Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8491 to 8505 of 8915 results

  1. Diabetes: annual care processes (children) (IND48)

    This indicator has been updated and replaced by NICE indicator 296 and NICE indicator 297.

    Withdrawn indicator

  2. Cardiovascular disease prevention: cholesterol treatment target (secondary prevention) (IND268)

    This indicator has been updated and replaced by NICE indicator 278.

    Withdrawn indicator

  3. Kidney conditions: CKD and SGLT2 inhibitors (IND262)

    This indicator has been updated and replaced by NICE indicator 322.

    Withdrawn indicator

  4. Multiple long-term conditions: falls prevention advice (IND209)

    This indicator has been removed following the publication of NICE guideline NG249.

    Withdrawn indicator

  5. Heart failure: beta blockers (IND194)

    This indicator has been updated and replaced by NICE indicator 317.

    Withdrawn indicator

  6. Heart Failure: ACEi or ARBs (IND193)

    This indicator has been updated and replaced by NICE indicator 317.

    Withdrawn indicator

  7. Asthma: annual review (IND188)

    This guidance has been updated and replaced by NICE indicator 273.

    Withdrawn indicator

  8. Asthma: objective tests (IND187)

    This guidance has been updated and replaced by NICE indicator 272.

    Withdrawn indicator

  9. COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Withdrawn advice

  10. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Withdrawn advice

  11. COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  12. COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)

    This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).

    Withdrawn advice

  13. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  14. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  15. RapidAI for analysing CT/MRI brain scans in people with suspected acute stroke (MIB262)

    This advice has been updated and replaced by NICE healthtech guidance 708.

    Withdrawn advice